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Abstract
Background The Medicines use review (MUR) service, provided by community pharmacists, seeks to optimise patients’ 
use of medicines. There is limited evidence on the clinical effectiveness of this service. Structuring MURs to include an 
assessment of prescribing appropriateness, facilitated by a validated prescribing screening tool, has the capacity to enhance 
this service. Objective To explore community pharmacists’ views on the facilitators and barriers towards the utilisation 
of a screening tool as a guide to conducting structured MURs. Setting Community Pharmacy, Northern Ireland. Method 
Using the 14 domain Theoretical Domains Framework (TDF), semi-structured interviews were conducted with community 
pharmacists. Interviews were digitally recorded, transcribed verbatim and analysed using the Framework method. Main 
Outcome Measure Pharmacists’ views towards utilisation of a screening tool as a guide to conducting structured MURs. 
Results Based on the analysis of 15 interviews, 11 TDF domains (‘Knowledge’, ‘Skills’, ‘Social and professional role and 
identity’, ‘Beliefs about capabilities’, ‘Beliefs about consequences’, ‘Reinforcement’, ‘Goals’, ‘Memory, attention and deci-
sion process’, ‘Environmental context and resources’, ‘Social influences’, ‘Behavioural regulation’) were deemed relevant. 
Facilitators included: knowledge of patients, clinical knowledge, perceived professional role, patients’ clinical outcomes, 
influence of peers. Barriers included: prioritisation of other clinical activities, inability to access patients’ clinical information, 
perceived alienation from the primary healthcare team and staffing issues. Conclusions Using the TDF, key facilitators and 
barriers were identified in the use of a screening tool as a guide to conducting MURs. These findings may assist in further 
development of MURs as a means to optimise patients’ medicines use.
Keywords Community pharmacists · Medicines use reviews · Older people · Prescribing appropriateness · Screening tools · 
Theoretical Domains Framework
Impacts on Practice
• This study explored community pharmacists’ views on 
the facilitators and barriers towards the utilisation of a 
screening tool as a guide to conducting structured medi-
cines use reviews (MURs).
• The main barriers identified were prioritisation of other 
clinical activities, inability to access patients’ clini-
cal information, perceived alienation from the primary 
healthcare team, staffing issues and perceived profes-
sional identity.
• To overcome these barriers there is a need to improve 
communication and collaboration between GPs and com-
munity pharmacists, staffing issues need to be addressed 
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and skills training in screening tool utilisation should be 
developed.
• This study provides preliminary data on the barriers and 
facilitators to utilising a screening tool as part of a MUR, 
which may assist in further development of MURs as a 
means to optimise patients’ medicines use.
Introduction
Prescribing for older people is complex, due to the increased 
likelihood of developing multiple long-term conditions 
(multimorbidity) and prescribing of multiple medications 
(polypharmacy) [1]. Polypharmacy is an essential com-
ponent in the management of multimorbidity, however it 
is associated with several undesirable outcomes such as 
reduced adherence to prescribed medication, drug–drug 
interactions and adverse drug reactions (ADRs) [1]; the lat-
ter is a particular concern in older people as the process of 
physiological ageing also renders this group more suscepti-
ble to ADRs [2]. Moreover, older people, particularly those 
with multiple long-term conditions, are routinely excluded 
from clinical drug trials and therefore the true safety and 
efficacy of many drugs has not been properly assessed in this 
population [3]. Consequently, the older age group are at an 
increased risk of potentially inappropriate prescribing (PIP), 
i.e. the under-, over- or mis-prescribing of medicines, which 
has been associated with ADRs, hospital admissions and 
mortality [4]. This has led to the development of a number 
of screening tools to evaluate the appropriateness of pre-
scribing, e.g. Screening Tool of Older Persons’ Prescriptions 
(STOPP) and Screening Tool to Alert doctors to Right Treat-
ment (START) [5, 6] and the Beers Criteria [7]. However, 
the potential of these tools to impact on long-term outcomes 
(e.g. mortality) has yet to be determined, since none is rou-
tinely used in clinical practice and there is a lack of robust 
data from randomised clinical trials [8].
One approach through which PIP can be identified and 
addressed is through an intervention such as a medication 
review. In an effort to improve prescribing and reduce poly-
pharmacy, there has been an international drive to involve a 
range of healthcare professionals in medicines management. 
One aspect of this has been the implementation of a formal 
medication review by community pharmacists to identify 
issues of poor adherence and medication-related problems 
e.g. medication use where there is no indication, untreated 
indications and sub-therapeutic dosages [9]. This service is 
offered to patients throughout the world, the characteristics 
of which differ depending on the country in which it is being 
offered. In Australia, this service is called the Collabora-
tive Home Medicine Review (HMR) service, Medication 
Therapy Management (MTM) service in the United States 
(US) [10] and Medicines use review (MUR) service in the 
United Kingdom (UK) [11].
In the UK, MURs are provided by accredited community 
pharmacists in the community pharmacy setting, in a suit-
able consultation area. The aim of a MUR is to improve 
patients’ adherence to therapy, ensure they are confident in 
using their medicines, resolve any problematic side-effects 
which may impede patients’ adherence to therapy and, in 
turn, improve the clinical and cost-effectiveness of pre-
scribed therapy [11]. In England, Wales and Northern Ire-
land, the MUR service focuses on target patient groups (e.g. 
those with a particular chronic condition, or those taking 
high-risk medicines such as warfarin) and eligible patients 
are identified by the pharmacist. Following the review, com-
pleted MUR documentation, which may include written rec-
ommendations on the clinical and/or cost-effectiveness of 
the prescribed therapy, are forwarded to the patient’s GP 
[12]. Community pharmacists have been provided with 
general guidelines on how MURs should be undertaken, 
however there is no specific screening tool recommended to 
assist pharmacists in the medication review process [13]. To 
date, current evidence regarding the clinical and cost effec-
tiveness of MURs has been inconclusive as there has been 
limited evidence reported on patients’ clinical outcomes 
[14]. Moreover, the quality of written reports provided to 
GPs and GPs’ hostility towards the service have been cited 
as further problems [15]. A small number of studies have 
explored pharmacists’, patients’ and GPs’ attitudes towards 
the MUR service. However, these results have been largely 
negative due to a variety of reasons such as patients’ per-
ception that MURs serve no purpose [9, 12], pharmacists’ 
perception that GPs did not endorse MURs [16], as well as 
a lack of collaboration between GPs and community phar-
macists [17].
The evident limitations of the MUR service present 
an opportunity to enhance this service [12]. For example, 
community pharmacists could undertake an assessment of 
prescribing appropriateness as part of a MUR, in an effort 
to improve prescribing, particularly in older people [9]. To 
facilitate this, MURs would need to be restructured to sup-
port community pharmacists in undertaking this assessment 
[18], e.g. through the application of a validated screening 
tool. To permit its use in the community pharmacy setting, 
the screening tool would be applied to medication data 
independent of clinical information and provide prescrib-
ing recommendations, to improve the appropriateness of 
prescribing. The enhancement of MURs (i.e. provision of a 
MUR to involve an assessment of prescribing appropriate-
ness) was beyond the scope of this study. However, if this 
were to be developed, it would be important to identify the 
potential barriers and facilitators to including an assessment 
of prescribing appropriateness within a MUR.
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Aim of the study
The aim of this study was to establish community pharma-
cists’ views on the barriers and facilitators towards utilisa-
tion of a screening tool as a guide to conducting structured 
MURs, to improve the appropriateness of prescribing in 
older people.
Ethics approval
Ethical approval was granted by the School of Pharmacy 
Ethics Committee, Queen’s University Belfast (QUB), on 
26th February 2015 (Reference No. 011PMY2015).
Method
The Theoretical Domains Framework (TDF) (12 domain 
[19] and 14 domain [20]) was developed by a group of 
experts as a means to help identify the factors (barriers and 
facilitators) to achieving behaviour change, particularly in 
the context of clinical practice. This study utilised the TDF 
to identify the barriers and facilitators towards utilisation of 
a screening tool as a guide to conducting structured MURs. 
Semi-structured interviews were conducted with community 
pharmacists using a TDF-based topic guide. This study was 
planned and reported in accordance with the ‘Consolidated 
criteria for reporting qualitative studies’ (COREQ) 32-item 
checklist [21].
Sampling and recruitment strategy
Participants were purposefully sampled using a convenience 
sampling approach. Community pharmacists working in 
pharmacies affiliated with the Community Pharmacy Place-
ment Network (which provides a structured placement pro-
gramme for undergraduate Pharmacy students) at the School 
of Pharmacy (QUB), who had undertaken the necessary 
training in the provision of MURs, were eligible for inclu-
sion in this study. At the time of this study, the Community 
Pharmacy Placement Network consisted of ~ 160 community 
pharmacies (which equated to ~ 32% of all community phar-
macies in Northern Ireland). An alphabetical list of com-
munity pharmacists within the sampling frame was accessed 
by the researcher (KC). This list contained data relating to 
the name of the pharmacist, place of work, address, email 
address and work telephone number. The researcher (KC) 
telephoned each community pharmacist in the order they 
appeared on the list, to inform them of the study and explain 
why they had been selected as a potential participant. There-
after, the researcher (KC) asked a screening question to con-
firm they had completed the necessary training in the provi-
sion of MURs. Community pharmacists, who expressed an 
interest in the study, were formally invited to participate in 
the study via an invitation letter, sent by email to the relevant 
community pharmacy, along with a study information sheet. 
Participants were given 1 week in which to decide whether 
they wished to participate. The anticipated sample size was 
approximately 20 participants. Recruitment continued until 
data saturation was reached, the identification of which was 
possible as data analysis was conducted in parallel to data 
collection. Participating pharmacists received an honorarium 
of £50 to cover their time committed to the study, (funded by 
The Harold and Marjorie Moss Charitable Trust), and were 
awarded a certificate of participation, following completion 
of the interview which could be used as evidence towards 
their Continuing Professional Development.
Design of the interview schedule
Semi-structured interviews were utilised as the method of 
data collection for this study as they provide participants 
with an opportunity to develop and express their views [22] 
and allow the researcher to explore unexpected themes, 
whilst maintaining the structure and focus required to 
answer the research question [23]. To identify the barriers 
and facilitators which may influence changes to service pro-
vision, an interview schedule was developed. It comprised 
questions that were based on each of the domains contained 
within the TDF-14 domain version. The interview schedule 
included a clinical scenario to illustrate how a screening tool 
could be utilised as a guide to conducting MURs in the com-
munity pharmacy setting, and participants were provided 
with definitions for a MUR, PIP and screening tools (see 
Supplementary Data). Pilot interviews were conducted with 
four experienced pharmacist researchers (who are also expe-
rienced community pharmacists) acting as the interviewee 
and, subsequently, interview schedules were refined.
Data collection
Interviews were conducted face-to-face by the researcher 
(KC) in suitable locations (either participants’ place of work 
or the School of Pharmacy, QUB). Interviews were recorded 
using a digital recorder, with the participants’ written con-
sent (obtained prior to the interview). Demographic data 
were also collected, to provide a description of the partici-
pating sample.
Data analysis
All participants were given a unique identifier to ensure con-
fidentiality (e.g. Community Pharmacist 1-CP1). Data were 
analysed using the Framework method [24]. The TDF-14 
domain served as the analytical framework, whereby each 
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of the 14 domains served as a coding category. Data analysis 
consisted of the following steps:
Transcription Interview audio-recordings were tran-
scribed verbatim (by the researcher [KC]) as soon as pos-
sible after the interview had taken place, which allowed 
the researcher (KC) to become familiar with the data [25]. 
Transcripts and audio recordings were stored on a password 
secure hard drive.
Familiarisation The familiarisation process involved 
repeated listening to the interview audio-recordings. All 
transcripts were checked for accuracy and imported into 
 NVivo® for analysis.
Coding Data were systematically coded by the researcher 
(KC) using a deductive approach, whereby each TDF-14 
domain [20] served as a coding category. Three interview 
transcripts were randomly selected and were coded inde-
pendently by two other members of the research team (CH, 
CR). The research team met to compare and agree upon 
the coding, and any coding discrepancies were resolved by 
consensus.
Charting The researcher (KC) charted (organised) the 
coded data into the framework matrix, which was generated 
as a Microsoft  Excel® spreadsheet [25].
Content analysis A content analysis of the framework 
matrix was then undertaken to identify subthemes (within 
each domain) relating to the barriers and facilitators to utilis-
ing a screening tool as a guide to conducting a MUR. The 
content analysis was completed using an inductive approach, 
as the subthemes that emerged during the content analy-
sis were not pre-defined. Subthemes within each domain 
were summarised to give an overall impression of how each 
domain may influence the use of a screening tool as a guide 
to conducting MURs; this was illustrated using supporting 
quotes.
A summary of the content analysis was reviewed by two 
members of the research team (KC and CR) and a consensus 
on the relevance of each domain was achieved. A domain 
was regarded as ‘relevant’ if it was coded frequently within 
the transcripts and if the content of the domain was specifi-
cally related to the utilisation of a screening tool as a guide 
to conducting MURs. Transcripts were not returned to par-
ticipants for comments and participants were not asked to 
provide feedback on the findings reported.
Results
Demographic overview of participating community 
pharmacists
In total, 18 pharmacists were recruited to take part in 
the study. Data saturation was deemed to have occurred 
at interview 15 as no new themes were identified by the 
researcher (KC) at this point. Therefore, three pharmacists 
who had previously been recruited for interview did not par-
ticipate and no repeat interviews were necessary. Of those 
interviewed, nine (60.0%) were female and six were male 
(40.0%). The average length of time participants had been 
practising as pharmacists was 12.1 years (range 2–34 years). 
Table 1 details the demographic information relating to the 
community pharmacists enrolled in this study. The average 
duration of each interview was 39 min (range 24–72 min).
Table 1  Demographic data of 
community pharmacists
CP community pharmacist
Pharmacist ID Gender Years practising as a 
pharmacist
Position Multiple/
independent 
pharmacy
CP1 Female 7 Pharmacy manager Multiple
CP2 Female 2 Pharmacy manager Multiple
CP3 Male 21 Pharmacy owner Independent
CP4 Female 18 Pharmacy manager Multiple
CP5 Female 11 Pharmacy manager Independent
CP6 Male 34 Pharmacy owner Independent
CP7 Male 8 Pharmacy manager Multiple
CP8 Female 24 Pharmacy manager Multiple
CP9 Female 4 Pharmacy manager Independent
CP10 Female 2 Pharmacist Independent
CP11 Male 20 Pharmacy manager Multiple
CP12 Male 9 Pharmacy manager Multiple
CP13 Female 12 Pharmacist Independent
CP14 Female 5 Pharmacist Independent
CP15 Male 5 Pharmacy manager Multiple
International Journal of Clinical Pharmacy 
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Identification of barriers and facilitators perceived 
to influence enhancement of the MUR service
Domains regarded as relevant to the utilisation of a screen-
ing tool as a guide to conducting MURs were: ‘Knowl-
edge’, ‘Skills’, ‘Social and professional role and identity’, 
‘Beliefs about capabilities’, ‘Beliefs about consequences’, 
‘Reinforcement’, ‘Goals’, ‘Memory, attention and decision 
process’, ‘Environmental context and resources’, ‘Social 
influences’ and ‘Behavioural regulation’. Those domains 
not regarded as relevant were: ‘Optimism’, ‘Intentions’ and 
‘Emotions’. Table 2 provides a definition for each relevant 
TDF domain, reports the subthemes identified within each 
relevant domain and provides illustrative quotes.
Discussion
Study synopsis
Using the TDF as the analytical framework, this study was 
an exploration of the barriers and facilitators, perceived by 
community pharmacists, towards the utilisation of a screen-
ing tool as a guide to conducting MURs. Based on the analy-
sis of 15 interviews, the TDF-domains considered relevant to 
the application of a screening tool in a MUR were: ‘Knowl-
edge’, ‘Skills’, ‘Social and professional role and identity’, 
‘Beliefs about capabilities’, ‘Beliefs about consequences’, 
‘Reinforcement’, ‘Goals’, ‘Memory, attention and decision 
process’, ‘Environmental context and resources’, ‘Social 
influences’ and ‘Behavioural regulation’. Restructuring and 
evaluating the MUR service would require a well-defined, 
robust methodological study, and was beyond the scope of 
this work. Nevertheless, this study serves as an explora-
tion of the factors which would influence changes to the 
provision of the MUR service. These barriers and facilita-
tors would need to be considered if the service were to be 
restructured. Subsequently, potential approaches to over-
coming the barriers (or enhancing the facilitators) identified 
are described below.
Potential approaches to overcoming the barriers (or 
enhancing the facilitators) identified
In an effort to overcome the barriers identified within the 
domains ‘Knowledge’, ‘Skills’ and ‘Beliefs about capabili-
ties’, it is essential to provide education and training for 
pharmacists. These training sessions should target deficits 
in clinical knowledge, and describe the evidence base [26], 
which in this instance relates to the improvement of pre-
scribing appropriateness, use of screening tools and the 
potential role of community pharmacists in improving pre-
scribing appropriateness. To develop pharmacists’ skills 
relating to the operation of a screening tool in a MUR, it is 
important to provide skills training which should include: 
instruction on how to use a screening tool in a MUR as well 
as an opportunity for pharmacists to utilise it in a controlled 
setting (i.e. in a workshop, facilitated by those experienced 
in operation of the tool) [27]. It is anticipated that educa-
tion and skills training would overcome pharmacists’ per-
ceived lack of clinical knowledge (‘Knowledge) and skill 
(‘Skills’) and, in turn, increase pharmacists’ confidence in 
their ability (‘Beliefs about capabilities’) to conduct MURs 
using a screening tool designed to identify instances of PIP. 
Thereafter, the provision of continued training and support 
would enable pharmacists to develop further their profes-
sional practice (‘Environmental context and resources’). One 
approach to this could involve the use of ‘helpful others’, 
which has been advocated by Harding and Wilcock [28], 
whereby pharmacists are supported in their clinical practice 
through shared learning networks such as intranet, email 
groups and in-person meetings with other pharmacists.
Whilst education and training are paramount in overcom-
ing the barriers associated with changing the provision of 
a service, they are not the only prerequisites. This has been 
evidenced in a study by Curran et al. [29] wherein education 
did not guarantee consistent application, by physicians, of a 
decision-making rule on the use of computed tomography. 
In this current study, although pharmacists had the desire 
to perform an increased number of MURs per week and 
believed the provision of MURs was part of their profes-
sional role, they recounted difficulty in achieving this due 
to restrictions on their time and limited availability of staff 
(‘Environmental context and resources’). This is consistent 
with previous research which has shown that pharmacists 
believe MURs are a valuable component of their profes-
sional role, but due to increasing work-loads and pressure 
from pharmacy managers to deliver on the quantity of 
MURs completed, pharmacists often undertake MURs with 
those patients on less complicated medication regimens. In 
turn, this prevents them from conducting a MUR with those 
patients who would benefit most and limits their opportunity 
to develop skills in providing MURs [28]. Thus, there is a 
need for pharmacy managers to address issues of inadequate 
staffing, to ensure that pharmacists have the appropriate level 
of support to allow them to fully embrace their clinical and 
professional role [17].
In this study, pharmacists supposed that GPs, other 
members of the primary healthcare team and patients ques-
tioned their professional role and clinical expertise regard-
ing medication reviews and the assessment of prescribing 
appropriateness. Moreover, they reported the frustration of 
not being able to contact the GP directly. This resulted in 
them feeling isolated from the rest of the primary healthcare 
team (‘Social and professional role and identity’; ‘Social 
influences’). This is a significant barrier to the enhancement 
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of the MUR service and is predominantly due to a lack of 
communication and collaboration between GPs and commu-
nity pharmacists. This issue has been identified in previous 
studies and patients have also recognised that this has the 
potential to cause conflict between their GP and pharmacist, 
and impact on their own relationship with their GP [17, 30]. 
On the whole, poor communication and lack of collabora-
tion between GPs and community pharmacists has been a 
longstanding and widespread issue in primary care [31–36]. 
This has led to the development of a number of theoretical 
models to understand factors associated with GP-community 
pharmacy collaboration [35].
In a recent qualitative study by Rathbone et  al. [37] 
researchers identified a number of determinants of success-
ful collaboration (between GPs and community pharmacists 
in Australia) to improve patients’ adherence to prescribed 
medicines. The barriers identified were a lack of shared 
location, a difference in perspectives, poor communication 
due to gatekeepers (GPs’ receptionists), irregular or volatile 
communication as well as a lack of mutual and professional 
respect. Conversely, the facilitators identified were access 
to a shared location, shared perspectives, face-to-face or 
electronic communication, regular communication as well 
as mutual and professional respect [37]. To overcome the 
barriers associated with ‘Social and professional role and 
identity’ and ‘Social influences’, collaboration between 
GPs and community pharmacists needs to improve. This 
could be facilitated through the provision of multidiscipli-
nary educational programmes, organised between local GP 
surgeries and neighbouring pharmacies [32]. In addition, 
there needs to be a more focused effort to improve collabo-
ration specific to the provision of MURs. Previous research 
has indicated the need to integrate clinical practice associ-
ated with the provision of MURs, in that MURs should be 
a shared partnership between community pharmacists and 
GPs, whereby patients are referred (by their GP) to their 
pharmacist for review [17]. As a result, GPs could be assured 
that the appropriate patients are being reviewed, pharmacists 
would have evidence that GPs approve of them conducting 
a medication review [27] and feelings of mutual and profes-
sional respect could be fostered [37].
In this instance, if the provision of MURs were to become 
a shared partnership between GPs and community pharma-
cists, ‘shared’ MUR documentation could be employed. Ide-
ally, this documentation would be electronic and include 
reminders, in an effort to overcome the barriers identified 
with the domains ‘Memory, attention and decision process’ 
(e.g. cognitive overload, forgetting to address issues identi-
fied in the MUR) and ‘Social influences’ (inability to contact 
the GP directly). Hypothetically, if both parties are aware 
of the issues to be addressed in the MUR, both could be 
held accountable for any decisions made, or lack thereof. 
GPs would know which MURs needed to be followed-up 
(‘Behavioural regulation’) and they would not be over-bur-
dened by endless (and perhaps irrelevant) MUR reports. As 
a result, both GPs and community pharmacists would have a 
vested interest in the MUR service, both would have shared 
perspectives and communication would be regular and pro-
active [37]. It is anticipated that, having overcome these bar-
riers, community pharmacists may prioritise the provision of 
MURs (using a screening tool to identify instances of PIP) 
(‘Goals’), and positive consequences (perceived by pharma-
cists) such as an enhanced MUR service, improved clinical 
outcomes for the patient and reduced healthcare costs could 
be attained (‘Beliefs about consequences’).
This study used a systematic approach to identify the 
theoretical domains associated with the utilisation of a 
screening tool as a guide to conducting MURs, as a means 
to improving the appropriateness of prescribing in older 
people. The systematic approach used in this study was 
informed by recommendations made in previous TDF-based 
studies [38, 39]. The refined (TDF-14 domain version) TDF 
was used as the analytical framework [20]. This version has 
a strengthened empirical base as it was derived from the 
original TDF-12 domain version [19]. Data collected for this 
study were analysed independently and decisions were made 
through consensus approaches, which added to the reliability 
and validity of the results reported. Moreover, two members 
of the research team (CH, CR) have extensive experience in 
using the TDF as an analytical framework. Finally, commu-
nity pharmacists recruited for this study were from a wide 
geographical area, working in independent pharmacies and 
pharmacy multiples, from both urban and rural settings. This 
should enhance the transferability of the findings from this 
study.
Despite the reported strengths of this study, there are also 
some limitations. Perhaps most obvious is the nature of the 
study. Since this is a qualitative analysis, the findings are 
not readily generalisable to the wider population. Whilst we 
appreciate that a convenience sampling approach has inher-
ent limitations, this method was chosen due to time restric-
tions. The sampling frame comprised 160 pharmacies within 
the Community Pharmacy Placement Network, equating to 
almost a third of all community pharmacies in Northern Ire-
land. It may be the case that pharmacists working in these 
pharmacies may engage more frequently in pharmacy prac-
tice research which may have biased the results, however 
it should also be noted that all pharmacists are required to 
undertake 30 h of CPD annually, irrespective of whether 
their pharmacy is part of the Pharmacy Placement Network 
or not. Participants enrolled in the study were incentivised to 
take part. Subsequently, the study sample was self-selected, 
which can result in self-selection bias. This study is also lim-
ited in that the views of other key stakeholders (e.g. GPs and 
patients) were not explored. Had time permitted, this could 
have been undertaken as part of a larger study. Although 
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this study discusses potential approaches to overcoming the 
barriers (and enhancing the facilitators) identified through 
the TDF domains, these approaches were not determined 
using the technique of mapping the domains to Behaviour 
change techniques (BCTs). The latter are considered to be 
the ‘active ingredients’ within an intervention [27]. Future 
research on this topic could follow this increasingly recog-
nised methodology, leading to the development of a theo-
retically informed intervention [40]. Finally, prior to under-
taking this piece of research, the researcher (KC) worked 
as a community pharmacist for a number of years. It was 
acknowledged that this could impart some bias to the data 
analysis process and subsequent findings reported in this 
study. However, in an effort to overcome this, a systematic 
approach to data analysis was undertaken and a consensus on 
the coding of transcripts and relevance of TDF domains was 
achieved between three researchers (KC, CH, CR).
Conclusion
Using the TDF, this study explored the barriers and facili-
tators perceived (by community pharmacists) to influence 
the utilisation of a screening tool as a guide to conducting 
MURs, as means to improving the appropriateness of pre-
scribing in older people. All domains (except ‘Optimism’, 
‘Intentions’ and ‘Emotion’) were identified as relevant to 
changing the provision of the MUR service. These findings 
form the basis for considering how the barriers can be over-
come and the facilitators enhanced.
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